$Can-Fite BioPharma (CANF.US)$ Ramat Gan, Israel, December 4...

$Can-Fite BioPharma (CANF.US)$ Ramat Gan, Israel, December 4, 2024 (Global News Network) - Can-Fite BioPharma Limited (NYSE: CANF) (Tel Aviv Stock Exchange: CANF) is a biotechnology company advancing proprietary small molecule drug development, focusing on cancer and inflammatory diseases. Today, it announced that in the second phase liver cancer study at Can-Fite, patients currently undergoing treatment with Namodenoson have an overall survival of 8 years in the compassionate use program. One patient, who previously participated in Can-Fite's second phase study and continued treatment with Namodenoson, has an overall survival of 8 years, with ascites disappeared, normal liver function, good quality of life, and defined as long-term complete responder.